| Literature DB >> 2080867 |
P G Higgins1, G I Barrow, D A Tyrrell, D Isaacs, C L Gauci.
Abstract
In a double-blind, placebo-controlled study, self-administered intranasal interferon alpha-2a or placebo was given both before and after challenge with respiratory syncytial virus. The incidence of colds and the severity of signs and symptoms were reduced in those receiving interferon alpha-2a as compared with those given placebo. In a further double-blind, placebo-controlled study, self-administered interferon alpha-2a or placebo was given only to those volunteers who developed colds following challenge with respiratory syncytial virus. There was no evidence that interferon alpha-2a reduced the severity of the signs and symptoms or shortened the duration of the illness. The similarity of these results to the effect of interferon alpha-2a in rhinovirus infections in volunteers is discussed.Entities:
Mesh：
Substances：
Year: 1990 PMID： 2080867 PMCID： PMC7134029 DOI： 10.1016/0166-3542(90)90061-b
Source DB: PubMed Journal: Antiviral Res ISSN： 0166-3542 Impact factor: 5.970